Compare TISI & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | OKYO |
|---|---|---|
| Founded | 1973 | 2007 |
| Country | United States | United Kingdom |
| Employees | 6800 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.4M | 87.6M |
| IPO Year | 1995 | 2021 |
| Metric | TISI | OKYO |
|---|---|---|
| Price | $26.52 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 26.8K | ★ 65.5K |
| Earning Date | 05-12-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $896,483,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $12.34 | $1.34 |
| 52 Week High | $25.33 | $3.20 |
| Indicator | TISI | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 76.73 | 53.81 |
| Support Level | $13.58 | $1.45 |
| Resistance Level | N/A | $1.73 |
| Average True Range (ATR) | 1.21 | 0.09 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 99.81 | 60.00 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.